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Abstract
Combining pharmacological treatments and life style interventions is necessary for effective therapy of major diseases
associated with obesity, which are clustered in the metabolic syndrome. Acting via multiple mechanisms, combination
treatments may reduce dose requirements and, therefore, lower the risk of adverse side effects, which are usually associated
with long-term pharmacological interventions. Our previous study in mice fed high-fat diet indicated additivity in
preservation of insulin sensitivity and in amelioration of major metabolic syndrome phenotypes by the combination
treatment using n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and rosiglitazone, i.e. an anti-diabetic drug of the
thiazolidinedione (TZD) family. We investigated here whether pioglitazone, a TZD-drug in clinical use, could elicit the
additive beneficial effects when combined with n-3 LC-PUFA. Adult male mice (C57BL/6N) were fed an obesogenic corn oil-
based high-fat diet (cHF) for 8 weeks, or randomly assigned to various dietary treatments (i) cHF+F, cHF with n-3 LC-PUFA
concentrate replacing 15% of dietary lipids; (ii) cHF+ROSI, cHF with 10 mg rosiglitazone/kg diet; (iii) cHF+F+ROSI; (iv)
cHF+PIO, cHF with 50 mg pioglitazone/kg diet; and (v) cHF+F+PIO, or chow-fed. Plasma concentrations of 163 metabolites
were evaluated using a targeted metabolomics approach. Both TZDs preserved glucose homeostasis and normal plasma
lipid levels while inducing adiponectin, with pioglitazone showing better effectiveness. The beneficial effects of TZDs were
further augmented by the combination treatments. cHF+F+ROSI but not cHF+F+PIO counteracted development of obesity,
in correlation with inducibility of fatty acid b-oxidation, as revealed by the metabolomic analysis. By contrast, only
cHF+F+PIO eliminated hepatic steatosis and this treatment also reversed insulin resistance in dietary obese mice. Our results
reveal differential effects of rosiglitazone and pioglitazone, unmasked in the combination treatment with n-3 LC-PUFA, and
support the notion that n-3 LC-PUFA could be used as add-on treatment to TZDs in order to improve diabetic patient’s
therapy.
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Introduction
Obesity-associated diseases, namely type 2 diabetes (T2D),
dyslipidaemia and other morbidities clustered in the ‘metabolic
syndrome’, predispose to cardiovascular disease and represent
major health problem around the world [1,2]. Complex ethiology
of these diseases involves both genetic and environmental factors
with a different contribution to disease progression in various
individuals. To improve the efficacy of the therapy of above
mentioned metabolic diseases, treatment strategies are typically
based on the use of combined treatments with multiple
mechanisms of action [3–5]. Such treatments optimally result in
synergistic beneficial effects, while reducing dose requirements and
the incidence of adverse side effects that are associated with most
of the chronic pharmacological interventions. Concerning T2D,
the major obesity-associated metabolic disease [6], thiazolidine-
diones (TZDs), namely rosiglitazone and pioglitazone, proved to
be useful for the pharmacological treatment of hyperglycaemia in
the patients, while used as add-on treatment to metformin [5] and
other pharmaceuticals [7]. However, due to a relatively high risk
of adverse cardiac effects, the use of rosiglitazone was banned by
the Europe in 2010 [8], whereas it is increasingly restricted by the
US Food and Drug Administration. Both TZDs may increase the
risk of osteoporosis (reviewed in [8]) and enhance accumulation of
body fat [9]. Pioglitazone but not rosiglitazone treatment improves
blood lipid profile in diabetic subjects [10] while differently
affecting HDL-cholesterol levels, as well as lipoprotein subclass
particle concentrations and particle sizes [11]. However, even the
safety of chronic pioglitazone therapy has been questioned by
recent unfavourable evidence [8,12]. Hence, a combination
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27126treatment, which would allow for a reduction in the effective dose
of pioglitazone (or other prospective new drugs from the TZD
family; see [13]), will be helpful for increasing the safety of the
therapy of diabetic patients.
Since TZDs are specific agonists of peroxisome-proliferator
activated receptor (PPAR) c, the major transcriptional regulator
in adipocytes, TZDs probably improve insulin sensitivity by (i)
increasing lipid uptake and mitochondrial b-oxidation in adipose
tissue [14], while reducing toxic effects of lipid accumulation in
other tissues (lipotoxicity); (ii) affecting distribution of body fat
through a decrease in the accumulation of abdominal fat and
promoting hyperplasia of adipocytes in subcutaneous fat [9]; and
(iii) inducing secretion of adiponectin [15,16], i.e. the major
adipokine with beneficial effects on insulin sensitivity. In addition,
PPAR-c-independent effects of TZDs have been described to
occur in both muscle and liver, documenting a very complex
mechanism of action of TZDs [15,17,18]. Moreover, also in
agreement with the differential effects of pioglitazone and
rosiglitazone on plasma lipids and lipoprotein observed in humans
(see above), animal studies suggest some differences between
pioglitazone and rosiglitazone in their effects on lipid metabolism.
Thus, in white adipose tissue of db/db mice, rosiglitazone induced
mitochondrial b-oxidation more strongly than pioglitazone [19],
while de novo lipogenesis in mouse liver was preferentially
stimulated by rosiglitazone [20–22]. In skeletal muscle, somehow
conflicting results concerning modulation of b-oxidation by
pioglitazone and rosiglitazone were found [23,24].
Besides pharmacological interventions, lifestyle changes are
inevitable in the treatment strategy of T2D patients and they are
extremely important for prevention of the disease [25]. The
patients may be advised [26] to increase their intake of n-3 long-
chain polyunsaturated fatty acids (LC-PUFA), namely eicosapen-
taenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA;
22:6n-3), either by consuming more sea fish or by means of
nutritional supplements. In humans, n-3 LC-PUFA act as
hypolipidaemics and increase HDL levels, while reducing
progression of atherosclerosis and cardiac events (reviewed in
[27,28]). The cardio protective effects were especially pronounced
in patients with T2D who have had myocardial infarction [29].
Several studies in humans demonstrated that n-3 LC-PUFA
supplementation could help to reduce obesity (reviewed in [30]).
However, n-3 LC-PUFA could not revert insulin resistance in T2D
patients [26,31,32]. Accordingly, in animal models, n-3 LC-PUFA
intake prevented development of insulin resistance [21,33–38],
obesity, and dyslipidaemia [21,37–41].
Both n-3 LC-PUFA [21,38,42,43] and TZDs [44] reduce low-
grade adipose tissue inflammation associated with obesity, as well
as systemic inflammation [45] in both humans and experimental
animals. Metabolic effects of n-3 LC-PUFA are largely mediated
PPAR-a and PPAR-d(-b), however liver X receptor-a, hepatic
nuclear factor-4, and sterol regulatory element binding protein-1
are also involved [46,47]. Besides acting directly as regulatory
ligands, n-3 LC-PUFA also act through their active metabolites,
eicosanoids [47], and other lipid mediators [48], and by inducing
adiponectin [35–37]. The hypolipidaemic and anti-obesity effects
of n-3 LC-PUFA probably depend on the suppression of
lipogenesis and increase of fatty acid oxidation in the liver [37],
as well as on the enhancement of mitochondrial biogenesis and b-
oxidation in white fat [41] and intestine [49], but not in skeletal
muscle [21,38].
Our recent results in dietary obese mice demonstrated that
rosiglitazone and n-3 LC-PUFA, both compounds administered at
a relatively low dose, exerted additive effects in prevention and
reversal of dyslipidaemia, low-grade inflammation of adipose
tissue, and insulin resistance, reflecting the induction of adipo-
nectin and synergistic improvement in muscle insulin sensitivity
[21]. These results suggested that inclusion of n-3 LC-PUFA in
TZD treatment may reduce dose requirements and incidence of
the adverse side effects associated with TZDs. Prompted by the
partially distinct biological effects of rosiglitazone and pioglitazone,
we compared the effects of rosiglitazone and pioglitazone
administered either singly or in combination treatments with n-3
LC-PUFA in mice fed a high-fat diet. Both TZDs prevented to
some extent dyslipidaemia and impairment of glucose homeostasis
and induced adiponectin. Rosiglitazone but not pioglitazone
potentiated the anti-obesity effect of n-3 LC-PUFA, reflecting
inducibility of fatty acid b-oxidation. The combination of TZDs
with n-3 LC-PUFA improved the effects on plasma lipid profile
and glucose homeostasis, which were stronger in case of
pioglitazone and correlated with its marked anti-steatotic effects
in the liver and with the induction of adiponectin.
Results
Prevention of obesity and anti-steatotic effects
Three-month-old mice (see Fig. 1) were randomly assigned to a
high-fat diet (lipid content ,35% wt/wt, mainly corn oil; cHF)o r
to the following ‘treatments’ by (i) cHF diet supplemented with n-3
LC-PUFA concentrate replacing 15% wt/wt of dietary lipids
(cHF+F); (ii) cHF diet supplemented with 10 mg rosiglitazone/kg
diet (cHF+ROSI); (iii) cHF diet supplemented with both n-3 LC-
PUFA concentrate and rosiglitazone (cHF+F+ROSI); (iv) cHF
diet supplemented with 50 mg pioglitazone/kg diet (cHF+PIO);
and (v) cHF diet supplemented with both n-3 LC-PUFA
concentrate and pioglitazone (cHF+F+PIO). While all the above
groups were fed isocaloric diets containing the same total content
of dietary fat, some mice were also fed standard laboratory diet
(Chow). Mice fed cHF diet gained body weight much faster than
those fed Chow (Fig. 2). Treatments by cHF+F, cHF+ROSI or
cHF+PIO tended to counteract the obesogenic effect of cHF diet.
As observed before [21], cHF+F+ROSI treatment reduced body
weight gain even further. In contrast, no effect of pioglitazone used
as add-on treatment to n-3 LC-PUFA (cHF+F+PIO) on body
weight was observed (Table 1, Fig. 2). None of the treatments
affected food consumption (Table 1).
The changes in body weight could be explained by modulation
of adiposity, as documented by weights of epididymal, mesenteric
and subcutaneous fat depots, with only the subcutaneous fat
reflecting the additive weight-reducing effects of the cHF+F+
ROSI treatment (Table 1). Accordingly, only cHF+F+ROSI but
not cHF+F+PIO treatment decreased plasma levels of leptin, the
major adipokine, the levels of which reflect the magnitude of fat
accumulation (Table 1). In both liver and skeletal muscle, cHF diet
increased triacylglycerol content (Table 1). None of the treatments
affected muscle lipid content. While cHF+F or cHF+F+ROSI
treatments had no significant effects on hepatic lipid content,
hepatic lipid content was increased by cHF+ROSI treatment as
compared with the cHF mice. In contrast, hepatic lipid content
was not affected by cHF+PIO treatment, and cHF+F+PIO
treatment even lowered hepatic lipids to the Chow mice levels
(Table 1). Both TZDs increased hepatic expression of the gene for
stearoyl-CoA desaturase-1 (SCD-1) that is essential for lipogenesis
(Table 1).
Plasma lipid levels, glycaemia and metabolic flexibility
During week 6 (see Fig. 1), plasma levels of NEFA,
triacylglycerols, and total cholesterol, and glycaemia were assessed
in both FASTED and RE-FED state (i.e., in mice with the
Thiazolidinediones and n-3 Fatty Acids
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doi:10.1371/journal.pone.0027126.g001
Figure 2. Body weights during differential dietary treatment. At 3 month of age, subgroups of mice were placed on cHF diet, or treated
various cHF-based diets: cHF+F, cHF+ROSI, cHF+F+ROSI, cHF+PIO and cHF+F+PIO, or maintained on Chow diet for 8 weeks. Irregularities of the body
weight caused by glucose tolerance test performed during week 7 (see Fig. 1) are apparent. Data are means 6 SE (n=7–8).
doi:10.1371/journal.pone.0027126.g002
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the dark phase of the day, when the feeding activity of all mice in
the cohort should be normally high; see Methods; Fig. 3). In both
states, higher levels of all these metabolic markers were detected in
the cHF mice as compared with the Chow mice, reflecting the
obesity and glucose intolerance developed in response to the high-
fat feeding (see below), except for (i) FASTED NEFA levels, which
were the highest in the Chow mice (Fig. 3A); and (ii) RE-FED
glycaemia, with all the groups showing similar levels (Fig. 3D).
Otherwise, all the treatments lowered the levels, or at least tended
to decrease them, hence preserving to a various degree the
‘healthy’ metabolic profile (see also metabolomic analysis below)
represented by the Chow mice. In most cases, the combination
treatments (cHF+F+ROSI and cHF+F+PIO) resulted in the
strongest effects, namely concerning the RE-FED triacylglycerol
levels (Fig. 3) and the cholesterol levels under both metabolic states
(Fig. 3C), and also the FASTED glycaemia tended to be
suppressed the most in response to the combination treatments
(Fig. 3D).
Metabolic adaptations to the FASTED/RE-FED transition are
known to be deteriorated in obese and insulin-resistant states
[1,50]. Indeed, the cHF mice showed smaller changes in the levels
of NEFA and glucose (Fig. 3A,D) and even opposite changes in the
levels of triacylglycerols (Fig. 3B) in response to the FASTED/RE-
FED transition as compared with the Chow mice. However,
cholesterol levels remained stable in mice fed both Chow and cHF
diet during the transition (Fig. 3C). None of the treatments
preserved the NEFA response, with the exception of the
cHF+F+ROSI treatment, which tended to normalize it (Fig. 3A).
In contrast to NEFA, the triacylglycerol response was fully
preserved by both combination treatments (cHF+F+ROSI and
cHF+F+PIO; Fig. 3B). Single-type treatments (cHF+F,
cHF+ROSI, and cHF+PIO) had no significant effect on the
triacylglycerol response. The glycaemic response tended to be
preserved by all the treatments, with only marginal differences
between them (Fig. 3D).
Thus, the plasma lipid levels and glycaemia measured under
both FASTED and RE-FED state, and the response of
triacylglycerol levels to the FASTED/RE-FED transition, docu-
mented much better preservation of the ‘healthy’ metabolic profile
by the combination treatments as compared with the single-type
treatments. Only subtle differences between the effects of
rosiglitazone and pioglitazone were observed, most consistently
in case of the triacylglycerol-lowering effect, with pioglitazone
showing a stronger effects in both single-type and cHF+F+PIO
treatments (Fig. 3B).
Glucose homeostasis
During week 7 (see Fig. 1), intraperitoneal glucose tolerance test
was performed (Fig. 4A,B,C). In accordance with the measure-
ments of blood glucose in the FASTED state (i.e., when food was
removed between 8:00 a.m. and 10:00 p.m.) during week 6
(Fig. 3D), baseline fasted glycaemia (time 0; Fig. 4A; food was
removed between 5:30 p.m. and 8:30 a.m.) in this case was ,1.6-
fold higher in the cHF mice than in the Chow mice (Fig. 4A,B).
This increase was fully prevented by the cHF+F treatment, as
well as by the combination treatments (cHF+F+ROSI and
cHF+F+PIO), while cHF+ROSI and cHF+PIO treatments tended
to had smaller effects. cHF-feeding impaired glucose tolerance
(Fig. 4A,C), while the treatments provided a similar kind of
Table 1. Growth characteristics, adiposity and lipid accumulation.
Chow cHF cHF+Fc H F +ROSI cHF+F+ROSI cHF+PIO cHF+F+PIO
Body weight (g)
Initial 29.660.9 29.960.7 29.3 0.8 29.060.9 28.860.8 29.360.6 28.960.7
Final 32.161.3 46.561.7
f 41.061.6 40.761.6 37.361.9
a 40.763.2 41.862.3
Body weight gain 2.160.6 16.061.2
f 11.760.8 11.561.2 8.161.3
a 11.362.9 12.161.7
FC (kJ/day/animal) 72647 2 626 9 627 0 626 5 627 1 626 5 61
Feed efficiency (mg BW/kJ) 3.260.6 27.462.7
f 17.862.6
a 20.661.6 16.761.3
a 20.461.8 23.761.7
Fat depots weights (mg)
Epididymal fat 7836129 32056243
f 2336686 22706263 22386287 22896479 21966187
Mesenteric fat 348622 12376168
f 711678
a 840682 6566105
a 8686146 607610
a
Subcutaneous fat 240637 968661
f 732684
a 58664
a 4046111
a,b 6366106
a 636683
a
Leptin (ng/ml) 8627 2 65
f 53645 8 610 4666
a 72610 6168
Triacylglycerol content (mg/g)
Liver 31638 7 610
f 5165
c 145629
a,b,d 75618
c 100618 3464
a,c,d,e
Muscle 18633 7 67
f 30673 4 623 5 662 9 663 9 64
Hepatic Scd-1 1.1060.06 0.1960.07
f 0.0960.04 0.5460.05
a,b 0.3460.11 0.4060.11
b 0.1660.05
c
Three-month-old mice were placed on various diets and killed after 8 weeks of the dietary treatment as described in Methods. Body weight and food consumption (FC;
recorded weekly) data are related to the initial 6 weeks of the treatment; due to irregularities of the body weight and FC data caused by glucose tolerance test
performed during week 7, data from the last 2 weeks of the treatment could not be included (see Fig. 1). Fat depot weights and levels of plasma leptin were recorded
after the killing. Expression of SCD-1 gene in the liver was evaluated using quantitative RT-PCR analysis and standardized using elongation factor 1a (Gene ID: 13627).
Data are means6SE (n=7-8).
aSignificantly different from cHF.
bsignificantly different from cHF+F.
csignificantly different from cHF+ROSI.
dsignificantly different from cHF+F+ROSI.
esignificantly different from cHF+PIO (ANOVA).
fSignificantly different from Chow (t-test).
doi:10.1371/journal.pone.0027126.t001
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above). Plasma insulin was also measured at the baseline and at
30 min after glucose injection (Fig. 4D), when the maximum
increase in glycaemia was expected (Fig. 4A). In the cHF mice, at
both time points, insulin levels were much higher as compared to
the Chow mice, and they also increased in response to glucose.
The effect of cHF diet was largely prevented by both combination
treatments, while single-type treatments showed smaller effects.
Pioglitazone lowered insulin levels more effectively as compared to
rosiglitazone, independent of the type of treatment (except for
cHF+ROSI vs cHF+PIO at the time 0; Fig. 4D). Changes in the
HOMA index supported the superior efficacy of the combination
treatments in the preservation of glucose homeostasis (Fig. 4E).
Thus, as compared with the preservation of various parameters of
glucose homeostasis by the single TZD-treatments (either
cHF+ROSI or cHF+PIO), the superior efficacy of the combina-
tion treatments was apparent. However, the difference was only
significant in case of plasma insulin levels in the cHF+F+PIO-fed
mice at 30 min (Fig. 4D). In neither situation, the effect of the
combination treatment was significantly ‘better’ as compared with
the effect of the single cHF+F treatment.
The above beneficial effects of various treatments on glucose
homeostasis could depend, at least in part, on the induction of
adiponectin (see Introduction). Indeed, plasma levels of total
adiponectin as well as of its biologically active high molecular
weight (HMW) form increased in response to cHF+F treatment
(Fig. 4F). Even a stronger induction was observed with both
combination treatments, and it was significantly stronger in case of
the cHF+F+PIO as compared with cHF+F+ROSI treatment.
Single-type treatments using either rosiglitazone or pioglitazone
had no effect (Fig. 4F). Thus, a remarkable synergism between n-3
LC-PUFA and pioglitazone in the induction of adiponectin was
found, resulting in ,2.3-fold and ,3.6-fold higher levels of total
and HMW adiponectin, respectively, as compared to the cHF mice.
Figure 3. Plasmatic lipids levels and glycaemia during FASTED/RE-FED transition. At 3 month of age, subgroups of mice were placed on
cHF diet, or treated various cHF-based diets. During week 6 of the treatment, plasma NEFA (A), triacylglycerols (B) and total cholesterol (C) levels and
blood glucose (D) were assessed in FASTED and in RE-FED state as described in Methods in mice fed by Chow or cHF diet, or treated by cHF+F,
cHF+ROSI, cHF+F+ROSI, cHF+PIO, and cHF+F+PIO diet. Data are means6SE (n=7–8).
a significantly different between FASTED and RE-FED state;
*significantly different from cHF;
{significantly different from cHF+F; {significantly different from cHF+ROSI;
#significantly different from cHF+F+ROSI
(ANOVA).
1Significantly different from cHF (t-test).
doi:10.1371/journal.pone.0027126.g003
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treatments on glucose homeostasis, two important issues remained
unclear, namely (i) how insulin sensitivity was affected by the
treatments, and (ii) whether the beneficial effects could be
demonstrated under the conditions of established obesity and
insulin resistance in dietary obese mice, i.e., under the situation
mimicking the status of human T2D patients. Therefore, mice
were fed cHF diet between 3 and 7 months of age to induce
obesity and to impair glucose homeostasis (see [21]), and then fed
either cHF diet, or subjected to cHF+F, or cHF+PIO, or
cHF+F+PIO treatment for 2 weeks, until performing an insulin
tolerance test (Figs. 1 and 5). During 30 min following insulin
injection, a uniform decline of glycemia was observed in all the
groups, and at 60 min after the injection, differences between
groups started to appear but they were not statistically significant.
At 90 min after the injection, when glycemia in all the groups
Figure 4. Preservation of glucose homeostasis during high-fat feeding by differential dietary treatment. At 3 month of age, subgroups
of mice were placed on cHF diet, or treated various cHF-based diets. During week 7 of the treatment, glucose tolerance test was performed (A–C).
A. Plasma glucose levels following i.p. glucose injection (time 0) to mice fed by Chow or cHF diet, or treated by cHF+F, cHF+ROSI, cHF+F+ROSI,
cHF+PIO, and cHF+F+PIO diet. B. Fasting blood glucose levels at the baseline (time 0; see A). C. Total area under the glycaemic curve values as above
(A). D. Insulin levels in plasma (at time 0 and at 30 min); lines and symbols as above (A). E HOMA index calculated from glucose and insulin plasma
levels at time 0. F. Adiponectin levels in plasma at time 0; bar height, total immunoreactive adiponectin; black section, low molecular weight
adiponectin; gray section, medium molecular weight adiponectin; white section, high molecular weight adiponectin; corresponding SE values are
indicated. B–F. Data are means6SE (n=7–8).
a significantly different between 0 min and 30 min. *Significantly different from cHF;
{significantly
different from cHF+F; {significantly different from cHF+ROSI;
#significantly different from cHF+F+ROSI;
$significantly different from cHF+PIO (ANOVA).
1Significantly different from cHF (t-test). AUC, area under the curve; AU, arbitrary units; FBG, fasting blood glucose.
doi:10.1371/journal.pone.0027126.g004
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showed significantly lower blood glucose leves as compared to the
cHF mice, and both groups subjected to single treatment (i.e., the
cHF+F and cHF+PIO mice) tended to show intermediate
glycemia (Fig. 5). Thus, these results documented a reversal of
insulin resistance in obese mice in response to the combination
treatment using n-3 LC-PUFA and piogliotazone, and they are in
accordance with the additive/synergistic mechanism of action of
the combination treatment (see Discussion).
Targeted metabolomics
In order to characterise further differential effects of various
treatments, plasma concentrations of 163 metabolites (Table S1)
providing representative sets of amino acids, sugars, acylcarnitines
and phospholipids were measured using flow injection analysis/
thermospray mass spectrometry (FIA-MS) with Biocrates Abso-
luteIDQ
TM targeted metabolomics technology. Plasma samples
collected in both FASTED and RE-FED states during week 6
were analysed (see also Fig. 3). Due to a relatively large error of
their quantification, 27 metabolites were excluded (Table S1) from
all the analyses described below. Partial least squares-discriminant
analysis (PLS-DA) of all the data separated mice into two distinct
groups, reflecting their feeding status, while the effect of the dietary
treatment was smaller ( Fig. S1). Following contribution score
analysis (Fig. S2), metabolites discriminative between the FASTED
and RE-FED states were identified. Most of acylcarnitines
increased in response to fasting, while all amino acids levels were
elevated in the RE-FED state among all the groups (see also ref.
[50]). With a few exceptions, also phosphatidylcholines (namely
diacyl-phosphatidylcholines with C30 - C36 side chains, and acyl-
alkyl-phosphatidylcholines with C34 - C38 side chains) and
lysophosphatidylcholines with C14 - C18 side chains increased
in general in response to re-feeding (Fig. S2).
Heat map correlation plots revealed stronger separations
between treatments in RE-FED (Fig. S3), as compared with the
FASTED state (Fig. S4). As expected, metabolomes of the Chow
mice and the cHF mice showed vast differences, and also the cHF
and the cHF+F mice differed in the concentrations of most lipids
determined. However, relatively small differences in metabolome
between the cHF+ROSI and the cHF+PIO mice, as well as
between the cHF+F+ROSI and the cHF+F+PIO mice were
observed (Fig. S3 and Fig. S4). Several metabolites could be
unequivocally identified, which showed meaningful changes in
their concentrations across all the groups. Namely the contents of
C18:2-, C18:0- and C20:4-lysophosphatidylcholine acyls, repre-
senting 3 out of 6 most abundant lysophosphatidylcholine acyl
species present (Table S1), were higher in the cHF mice than in
the Chow mice, especially in the RE-FED state (Fig. 6A,B,C). This
elevation was compromised by all the treatments, in accordance
with the known association of the above lipids with obesity-
induced low-grade systemic inflammation [51,52], and suggesting
amelioration of the inflammatory state by the treatments. The
combination treatments tended to exert the most pronounced
effects (Fig. 6A,B,C). The content of 20:4-lysophosphatidylcholine
increased in response to RE-FED state in all mice fed cHF-based
diets, but in the Chow mice. Its levels in the cHF+F,
cHF+F+ROSI and cHF+F+PIO mice were very low (Fig. 6C).
The main focus of the analyses was on detailed characterisation
of the differential effects of rosiglitazone and pioglitazone. We
hypothesised that the discriminating metabolites might be found
based on their response to the FASTED/RE-FED transition, as
suggested by this type of analysis performed with plasma NEFA,
triacylglycerols, and glucose (see Fig. 3A,B,D). First, the difference
in each metabolite concentration between RE-FED and FASTED
state (DV) was analysed using PLS-DA, reflecting the diet, in the
cHF, cHF+ROSI and cHF+PIO mice. The first (axis X) as well as
Figure 5. Reversal of insulin resistance in obese mice by differential dietary treatment. Mice were fed cHF diet between 3 and 7 months
of age and then fed cHF diet, or treated by cHF+F, cHF+PIO, and cHF+F+PIO diet for 2 weeks (n=8). Plama glucose levels in mice subjected to insulin
tolerance test are shown. Body weights of the groups were similar at the beginning of the dietary intervention (average body weight cHF,
42.261.9 g; cHF+F, 41.962.1 g; cHF+PIO, 41.862.4 g; and cHF+F+PIO , 41.961.8 g), as well as after 2 weeks of the intervention (not shown). Fasting
blood glucose level at beginning of the test were similar in all the groups (cHF, 12.460.7 mmol/l; cHF+F, 12.460.7 mmol/l; cHF+PIO, 10.660.6 mmol/
l; and cHF+F+PIO, 9.060.4 mmol/l). *significantly different from cHF (ANOVA).
doi:10.1371/journal.pone.0027126.g005
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between the cHF mice and the TZD-treated mice, however no
separation between the cHF+ROSI and cHF+PIO mice could be
observed (Fig. 7A), indicating similar changes in the concentra-
tions of most of the measured metabolites during the FASTED/
RE-FED transition, independent of the type of TZD. When the
cHF, cHF+F+ROSI and cHF+F+PIO mice were analysed, the
first PLS-DA component showed a strong separation between the
cHF mice and mice subjected to the combination treatments.
Importantly, in contrast to a lack of separation between the single-
TZD-treatments, the second PLS-DA component showed a
separation between two combination treatments (Fig. 7B). There-
fore, these data were further analysed to identify metabolites
discriminating between the cHF+F+ROSI and cHF+F+PIO mice.
Contribution scores indicated that namely various acylcarnitines
contributed to the separation of these two combination treatments
(Fig. 7C and Fig. S5). Even side-chain species acylcarnitines in
plasma, and especially those with longer chains, reflect activity of
mitochondrial b-oxidation [50,53,54]. Acylcarnitines with satu-
rated (Fig. 8A) and monounsaturated (Fig. 8B) even side-chains
C12-C18 showed lower levels in RE-FED as compared with
FASTED state, and the response to FASTED/RE-FED transition
of these lipids discriminated between cHF+F+ROSI and
cHF+F+PIO treatments, while tetradecenoylcarnitine (C14:1)
and palmitoleylcarnitine (C16:1) represented the major discrimi-
nating metabolites (Fig. 8B), in fact 2 out of 4 metabolites with the
contribution scores .2 (Fig. 7C and Fig. S5). The majority of
metabolites including acylcarnitine showed a bigger response to
FASTED/RE-FED transition in the case of cHF+F+ROSI as
compared to cHF+F+PIO treatment. Levels of acylcarnitines with
shorter even side-chains (C,10) were not affected by the feeding
status (Fig. 7A,B and Fig. S5).
Discussion
We have shown that a long-term treatment combining n-3 LC-
PUFA and either rosiglitazone or pioglitazone markedly improved
systemic markers of lipid and glucose homeostasis in mice fed a
high-fat diet. However, differences between the effects of
rosiglitazone and pioglitazone became apparent under the
conditions of the combination treatment, especially with respect
to the unique anti-obesity effect of the treatment using rosiglita-
zone, and relatively strong insulin-sensitizing and hypolipidaemic
effects of the pioglitazone-based treatments.
We have confirmed our previous finding [21] that the
combination treatment using relatively low doses of rosiglitazone
and n-3 LC-PUFA exerted surprising additive effects in the
prevention of body weight gain, namely due to a reduced
accumulation of subcutaneous fat. This is in contrast with the
enhanced accumulation of subcutaneous fat in diabetic patients
treated with rosiglitazone [9], as well as in mice treated by
rosiglitazone using the doses much higher than here (e.g. refs.
[14,15] and our previous study [21]) and eliciting a strong insulin-
sensitizing effect [14]. At the dose used in this study, rosiglitazone
had no effect on hepatic insulin sensitivity [21]. In a sharp contrast
with rosiglitazone, pioglitazone did not affect body weight and
adiposity when used in the combination treatment. These results
Figure 6. Chemical concentrations of various lysophosphati-
dylcholines measured in plasma in the FASTED and RE-FED
state in all groups of mice. At 3 month of age, subgroups of mice
were placed on cHF diet, or treated various cHF-based diets. During
week 6 of the treatment, targeted metabolomics analysis was
performed. Changes in concentrations of selected analytes are shown
(see text, see Fig. 7). A. linoleoyl lysophosphatidylcholine (C18:2). B.
stearoyl lysophosphatidylcholine (C18:0). C. arachidonoyl lysophospha-
tidylcholine (C20:4). Data are means6SE (n=7–8).
asignificantly
different between FASTED (black bars) and RE-FED (white bars) state;
*significantly different from cHF; {significantly different from cHF+ROSI;
$significantly different from cHF+PIO (ANOVA).
1Significantly different
from cHF (t-test).
doi:10.1371/journal.pone.0027126.g006
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27126Figure 7. Comparisons of the effects of treatment by TZD-containing diets on plasma metabolome. At 3 month of age, subgroups of
mice were placed on cHF diet, or treated various cHF-based diets. During week 6 of the treatment, targeted metabolomics analysis was performed. In
total, plasma concentrations of 163 metabolites were determined in both FASTED and RE-FED states during week 6 of the treatment using FIA-MS
with the Biocrates AbsoluteIDQ
TM targeted metabolomics technology. After removal of unstable metabolites (see Table S1), 136 metabolites were
included in a partial least squares-discriminant analysis (PLS-DA), using delta values (DV) calculated as a difference in the concentration (c) of each
metabolite between RE-FED and FASTED state in individual mice (DV = RE-FEDc – FASTEDc). 2D-scatter plots of the first (axis X) and the second (axis
Y) PLS-DA component are shown for selected groups of mice (n=7–8). A. Mice fed cHF diet (black circles), or treated using cHF+ROSI (green circles)
or cHF+PIO diet (red circles). B. Mice fed cHF diet (black circles), or treated using cHF+F+ROSI (violet circles), or cHF+F+PIO (cyan circles) diet.
C. Contribution scores for the separation between the cHF+F+ROSI and cHF+F+PIO treatments (see B) for each metabolite are shown. Positive value
of the score corresponds to a larger DV of the metabolite in the cHF+F+ROSI as compared with the cHF+F+PIO mice. Metabolites with contribution
scores .2.0 are labeled (for figure in a zoomable format, see Fig. S5; see Table S1 for the full list of the metabolites and the abbreviations). AA, amino
acid; PC, phosphatidylcholine; LysoPC, lysophosphatidylcholine; SM, sphingomyeline and hydroxysphingomyeline.
doi:10.1371/journal.pone.0027126.g007
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DHA were administered as phospholipids rather than triacylgly-
cerols (Rossmeisl et al, unpublished).
The differential anti-obesity effect of the two TZDs in the
combination treatments correlated with changes in plasma levels
of acylcarnitines with long saturated and monounsaturated even
side-chains (C12-C18) in response to re-feeding. Plasma levels of
these lipids correlate with the activity of b-oxidation, mainly in
skeletal muscle [50,54], and also in the liver [55], while they are
suppressed by insulin, thus reflecting the switch between fatty acid
and carbohydrate catabolism [53,56]. High-fat diet-induced
insulin resistance in skeletal muscle is characterised by an impaired
switching to carbohydrate oxidation during the FASTED/RE-
FED transition, which is mirrored by smaller changes in the tissue
levels of long-chain acylcarnitines [50]. Accordingly, the stronger
suppression of plasma levels of the long-chain acylcarnitines in
response to re-feeding in the cHF+F+ROSI as compared with the
cHF+F+PIO mice suggest that the anti-obesity effect of the
cHF+F+ROSI treatment reflects the relatively strong stimulation
of b-oxidation. The anti-obesity effect was also reflected by the
response of NEFA levels in plasma to the FASTED/RE-FED
transition. Negligible effects of the treatments on the plasma b-
hydroxybutyrate levels, independent of the metabolic status (Table
S1), suggest that lipid catabolism in the muscle rather than in the
liver was affected differentially by two types of combination
treatments. That the combination treatment using n-3 LC-PUFA
and rosiglitazone specifically induced whole body lipid catabolism
was not expected, based on the effects of single-type treatments
using rosiglitazone or piogliazone [23,24]. Thus, the combination
treatment could unmask interactions, which caused strong and
unexpected biological effects.
The changes in plasma metabolome indicated amelioration of
systemic inflammation associated with obesity, namely by the
combination treatments, as documented by decreased levels of
several lysophosphatidylcholine species, observed also before with
both fish oil feeding [51,52] and metformin therapy in humans
[57]. In contrast to linoleoyl lysophosphatidylcholine (C18:2) and
stearoyl lysophosphatidylcholine (C18:0), arachidonoyl lysophos-
phatidylcholine (C20:4) levels were increased by re-feeding only in
the dietary obese mice but not in the lean Chow mice, while the
suppression of this metabolite levels by n-3 LC-PUFA containing
diets was very strong, suggesting a replacement of arachidonic acid
(AA; C20:4n-6) in lysophosphatidylcholine by EPA and DHA.
Such changes in phospholipid fatty acid composition in obese mice
could occur also intracellularly and might have a dramatic impact
on eicosanoid formation from PUFA released from membrane
phospholipids, while decreasing the formation of pro-inflammato-
ry (AA-derived) and enhancing formation of anti-inflammatory (n-
3 LC-PUFA-derived) lipid mediators [38,42,43,48].
The additivity in improvement of glucose homeostasis and in
preservation of insulin sensitivity was proved previously using
cHF+F+ROSI treatment and hyperinsulinaemic-euglycaemic
clamps during development of obesity in mice [21]. This was in
agreement with the suppression of plasma insulin levels during the
glucose tolerance test by both types of combination treatments,
which was stronger with pioglitazone as compared to rosiglitazone,
also in accordance with the highest induction of adiponectin by the
cHF+F+PIO treatment. Moreover, insulin tolerance test perfomed
in dietary obese mice in this study suggested that the combined use
of n-3 LC-PUFA and pioglitazone could provide an additive benefit
in reverting insulin resistance. These findings have implications for
the treatment of insulin resistance in diabetic patients, concerning
the facts that the beneficial effect on insulin sensitivity could be
demonstrated under the conditions of established obesity and
insulin resistance,and that pioglitazone,i.e.the only TZDapproved
for clinical use at present, was shown to exert the effect.
In analogy to the situation in humans [10], pioglitazone also
exerted stronger triacylglycerol-lowering effects, namely under the
RE-FED state. In fact, the cHF+F+PIO treatment resulted not
only in the lowest plasma triacylglycerol levels, but also fully
prevented the cHF-induced hepatic steatosis, suggesting that (i) the
hypolipidaemic effect resulted from the modulation of hepatic lipid
Figure 8. Concentrations of selected even-chain acylcarnitines
measured in plasma in the FASTED and RE-FED state in the
cHF+F+ROSI and cHF+F+PIO mice. Data are means6SE (n=7–8). A.
Saturated acylcarnitines. B. Monounsaturated acylcarnitines. Individual
acylcarnitines are denoted by their side chains; see Table S1 for the
concentrations all 26 acylcarnitines determined. Axis Y, concentration of
each carnitine (mM); gray background, acylcarnitines showing the
largest contribution scores (.2) in the separation between the
cHF+F+ROSI and cHF+F+PIO mice (see Fig. S5).
asignificant difference
between FASTED (black bars) and RE-FED (white bars) state;
#significantly different from cHF+F+ROSI (ANOVA).
doi:10.1371/journal.pone.0027126.g008
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formation, and (ii) the hepatic effects were mediated by AMP-
activated protein kinase (AMPK), stimulated by adiponectin. This
would be in agreement with the involvement of the adiponectin-
AMPK axis in the effects of both TZDs [58] and n-3 LC-PUFA
[37], with the modulation of hepatic metabolism by n-3 LC-PUFA
[37] and with the relatively strong activation of hepatic AMPK in
response to pioglitazone [22]. The synergistic anti-steatotic effect
of the cHF+F+PIO treatment is even more striking in the light of
the opposite effects elicited by TZDs, concerning both hepatic
steatosis and Scd-1 expression. We have found previously [20,21]
that SCD-1 activity was stimulated by cHF+ROSI treatment,
resulting in elevated formation of palmitoleate and increased
hepatic triacylglycerol content. We show here that also pioglita-
zone, when administered singly, exerts a similar effect on hepatic
lipid metabolism as rosiglitazone. However, this effect is less
pronounced (see also [22]) and it could be overridden by the
combination treatment, documenting potent synergistic interac-
tions between pioglitazone and n-3 LC-PUFA, resulting in the
pronounced anti-steatotic effect.
In analogy with other combination therapies in the field of
metabolic syndrome, namely the combined use of n-3 LC-PUFA
and simvastatin in subjects treated for hypertriglyceridaemia [3],
our experiments on dietary obese mice suggest that also n-3 LC-
PUFA and TZDs may elicit beneficial additive effects with respect
to treatment of impaired glucose tolerance and dyslipidaemia in
diabetic patients. Thus in mice, only rosiglitazone but not
pioglitazone in the combination with n-3 LC-PUFA prevented
accretion of bodyfat, incorrelation with theinducibility offatty acid
b-oxidation. However, even in the absence of any effect on body
weight, the combination treatment unmasked stronger effect of
pioglitazone on glucose homeostasis, triglyceridaemia and hepatic
steatosis, depending probably on the induction of adiponectin. It
would be interesting to test whether a combination treatment using
n-3 LC-PUFA and a lower dose of pioglitazone could exert anti-
obesity effect or whether a combined use of n-3 LC-PUFA and both
TZDs could provide a more complex benefit. Importantly, total
cholesterol levels in plasma were strongly decreased in response to
both TZDs in their combinations with n-3 LC-PUFA.
In spite of the concerns related to the adverse side effects of the
TZD-based therapy [5,8], the US Endocrinology Society in its
recent statement [61] recommends "to continue the search for
additional safe and effective drugs in this class", based on the
notion that "adverse events suggests that they might be specific
effects related to the individual drug make-up rather than a class
effect characteristic of all thiazolidinedione drugs". Accordingly,
our results document further that biological effects of various TZD
drugs are rather specific, and the differential effects may be
unmasked in combination treatments. Our results suggest that n-3
LC-PUFA could be used as add-on treatment to pioglitazone, as
well as to other prospective drugs from the TZD family (or to
structurally diverse PPAR-c modulators; see [13]), to increase the
efficacy of the treatment in diabetic patients and, hence, to
decrease the dose requirements of the therapy. The protection
against cardiovascular disease mortality of diabetic patients in
response to increased n-3 LC-PUFA intake [29] represents an
important argument in favour of the inclusion of these lipids in the
combination treatment of diabetic patients.
Methods
Animals and treatments
Male C57BL/6N mice (Charles River Laboratories, Sulzfeld,
Germany) were maintained at 22uC on 12-h light-dark cycle (light
from 6.00 a.m.) with free access to water and Chow (lipid content
,3.4% wt/wt; extruded Ssniff R/M-H diet; Ssniff Spezialdieten
GmbH, Soest, Germany). Except for the evaluation of insulin
sensitivity in dietary obese (see below, see Fig. 5), three-month-old
mice (Fig. 1) were randomly assigned (n=8; 2 animals per cage) to
cHF diet (lipid content ,35% wt/wt, mainly corn oil; [21]) or to
the following ‘treatments’ by (i) cHF+F, cHF diet supplemented
with n-3 LC-PUFA concentrate (46% DHA, 14% EPA, wt/wt, as
triacylglycerols; product EPAX 1050 TG; EPAX a.s., Lysaker,
Norway), which replaced 15% wt/wt of dietary lipids; (ii)
cHF+ROSI, cHF diet supplemented with 10 mg rosiglitazone/
kg diet (Avandia; GlaxoSmithKline, USA); (iii) cHF+F+ROSI,
cHF diet supplemented with both n-3 LC-PUFA concentrate and
rosiglitazone; (iv) cHF+PIO, cHF diet supplemented with 50 mg
pioglitazone/kg diet (Actos; Takeda, Japan); and (v) cHF+F+PIO,
cHF diet supplemented with both n-3 LC-PUFA concentrate and
pioglitazone. During the treatment lasting for 8 weeks (week 1 –
week 8; see Fig. 1), fresh ration of food was distributed daily and
food consumption and body weights were recorded once a week.
Eventually, to analyse all the animals under identical nutritional
conditions, mice were fasted during the day (between 8.00 a.m.
and 6.00 p.m.), and then allowed free access to Chow during the
night and in the morning until the time of killing the animals
under pentobarbital anaesthesia (between 9.00 and 11.00 am).
Liver and gastrocnemius muscle were dissected and EDTA-plasma
was isolated and stored for further analyses. To characterize the
effect of the treatment on insulin sensitivity in obese mice, a separate
experiment was performed, in which all the animals were fed cHF
diet between 3 and 7 months of age, and then singly caged animals
were randomly assigned (n=8) to cHF diet, or they were treated by
cHF+F, or cHF+PIO, or cHF+F+PIO diet for 2 weeks, i.e. the time
when insulin tolerance test was performed (see below).
The animal experiments were specifically approved by the
Animal Care and Use Committee of the Institute of Physiology
Academy of Sciences of the Czech Republic v.v.i. (Approval
Number: 172/2009) and conducted under the guidelines.
Plasma variables
When indicated, EDTA-plasma was collected using tail
bleeding in both FASTED and RE-FED state, as before [59].
Thus, before the bleeding, one half of mice within each
experimental group was either (i) fasted for 14 hours (food was
removed between 8:00 a.m. and 10:00 p.m., while mice were kept
in a clean new cage), or (ii) fasted for 10 hours (between 8:00 a.m.
and 6:00 p.m.) and allowed free access to food for the following 3
hours. In each mouse, NEFA, triacylglycerols, leptin and total
cholesterol in EDTA-plasma, and glycaemia were assessed as
before [21], and plasma levels of b-hydroxybutyrate levels were
determined using Autokit 3-HB (Wako Chemicals, Germany,
Neuss) with calibration to Ketone Body Calibrator (Wako
Chemicals, Germany, Neuss), in both FASTED and RE-FED
state, while altering the above protocols during the two subsequent
days. Multimeric forms of adiponectin in FASTED plasma were
determined using Western blotting [59].
In addition, in 0.01 ml plasma-aliquots collected in both
FASTED and RE-FED state, concentrations of 163 metabolites
were determined using a metabolomics kit (AbsoluteIDQ
TM kit
p150, Biocrates Life Sciences AG, Innsbruck, Austria) based on
FIA-MS as before [60]. Concentrations of all analysed metabolites
are reported in mM. When indicated, response of each metabolite
to the FASTED/RE-FED transition in individual mice was
calculated as a difference (DV) in the metabolite concentration (c)
under the two feeding states (DV = RE-FEDc – FASTEDc). For
the general information on biological roles of the metabolites, see
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acylcarnitines, 14 hydroxy- and dicarboxy-acylcarnitines, 10
sphyngomyelins, 5 hydroxysphyngomyelins, 38 diacyl-phosphati-
dylcholines, 39 acyl-alkyl-phospatidylcholines, and 15 lysophos-
phatidylcholines were identified. For the full list of the measured
metabolites and the abbreviations to denote them, see Table S1.
To ensure the data quality, 27 unstable metabolites were removed,
based on the low (#0.25) coefficient of variance of the same 10
reference samples or large proportion (.10%) of measured
samples below the limit of detection (LOD; see Table S1).
Glucose homeostasis
Intraperitoneal glucose tolerance test was performed in
overnight fasted mice (food was removed between 5:30 p.m. and
8:30 a.m., i.e the time of the start of the test by the injection of D-
glucose (1 g/kg body weight); ref. [59]), in which glycaemia was
assessed using tail bleeds just before the injection (fasting blood
glucose at the baseline), and during 180 min after the injection
using glucometers (LifeScan, USA). Insulin levels were also
determined at the baseline and 30 min after the glucose injection.
HOMA index was calculated by the following formula: FASTED
plasma insulin (mU/l) x FASTED plasma glucose (mmol/l) / 22.5
[38]. Insulin tolerance test was performed in mice starved for 4
hours (food was removed between 7 a.m. and 11 a.m.). At 0, 15, 30
and 90 min following i.p. injection of insulin (0.75 U/kg;
Actrapid, Novo Nordisk, Denmark), glucose levels in tail blood
were monitored as above.
Tissue lipid content and gene expression
Liver and muscle triacylglycerol content was estimated in
ethanol KOH solubilisates, and the levels of SCD-1 gene
transcript in total liver RNA was evaluated using quantitative
RT-PCR [21].
Statistical analysis
All values are presented as means6SE. Comparisons were
judged to be significant at p#0.05 (see Text S1). PLS-DA was
performed using Umetrics SIMCA-P+12 statistical software
(Umetrics AB, Umea, Sweden; see Text S1).
Supporting Information
Figure S1 Comparisons of the effects of feeding status
and treatments on plasma metabolome and identifica-
tion of discriminative metabolites. In total, plasma
concentrations of 163 metabolites were determined in both
FASTED (triangle symbols) and RE-FED (circle symbols) states
during week 6 of the treatment using FIA-MS with the Biocrates
AbsoluteIDQ
TM targeted metabolomics technology. After removal
of unstable metabolites (see Table S1), 136 metabolites were
included in a partial least squares-discriminant analysis (PLS-DA).
2D-scatter plots of the first (axis X) and the second (axis Y) PLS-
DA component are shown for all dietary treatments. First PLS-DA
component (axis X) separated mice into two distinct groups,
reflecting the feeding status and indicating that FASTED and RE-
FED states differed substantially in global metabolic profile. The
second PLS-DA component (axis Y) showed only a weak
separation, with a stronger difference between cHF and chow
diet. Different colours were used to indicate the diet and the
treatment as in Fig. 1 and Fig. 2.
(TIF)
Figure S2 The most discriminative metabolites identi-
fied using contribution score analysis. Contribution scores
for the separation between the FASTED and RE-FED state using
PLS-DA in Fig. S1, independent on the dietary treatment, for each
metabolite are shown. For the full list of 163 measured
metabolites, 136 metabolites included in the analysis and the
abbreviations to denote them, see Table S1. A positive
contribution score value indicates higher level of the metabolite
in FASTED as compared to RE-FED state (see also Table S1).
(TIF)
Figure S3 Hierarchial clustering of metabolites in
plasma with respect to dietary treatments. In total, plasma
concentrations of 163 metabolites were determined in RE-FED
state during the week 6 of the treatment using FIA-MS with the
Biocrates AbsoluteIDQ
TM targeted metabolomics technology.
After removal of unstable metabolites (see ESM Table 1), 136
metabolites were included in the analysis. The ratio of the
concentration of each metabolite in each dietary group to a
common reference pool is represented by the colour of each cell in
the heatmap (green and red, indicates increased and decreased
concentration, respectively; see also the Colour Key in the figure).
Vertical dendrogram, clustering of metabolites. Each square in the
heatmap represents x-fold change relative to mean concentration
of each metabolite in all mice (n=7-8) in a color-coded way. Data
analysis was performed under the R statistical environment
(http://www.r-project.org/). For the full list of 163 measured
metabolites, 136 metabolites included in the analysis and the
abbreviations to denote them, see Table S1.
(TIF)
Figure S4 Hierarchical clustering of metabolites in
plasma with respect to dietary treatments. As in Fig. S3,
but for FASTED state.
(TIF)
Figure S5 Contribution of individual metabolites (136
metabolites in total) to the global difference in plasma
metabolome between the cHF+F+ROSI and cHF+F+PIO
treatments. In addition to the combination treatment groups,
also the cHF mice were included in the partial least squares-
discriminant analysis (PLS-DA), which was performed using delta
values (DV) calculated as a difference in the concentration (c)o f
each metabolite between RE-FED and FASTED state in
individual mice; see Fig. 7B of the main text. Contribution scores
for the separation between the cHF+F+ROSI and cHF+F+PIO
treatments for each metabolite are shown (see also Fig. 7C).
Positive value of the score corresponds to a larger DV of the
metabolite in the cHF+F+ROSI as compared with the
cHF+F+PIO mice. Chemical concentrations of acylcarnitines
measured in plasma in the FASTED and RE-FED states are
shown in Fig. 8 of the main text. For the full list of measured
metabolites and the abbreviations to denote them, see Table S1.
(TIF)
Table S1 List of all 163 metabolites measured in
plasma - targeted metabolomics See separate files for
the tabulated data (both as a pdf file and an Excel sheet).
In short, 14 amino acids, sum of hexoses (H1), free carnitine (C0),
26 acylcarnitines (C2, C3,…C18:2), 14 hydroxy- and dicarboxy-
acylcarnitines (C-3OH, C4-OH, C5-DC,…C18:1-OH), 10 sphyn-
gomyelins (SM C16:0, SM C16:1,… SM C26:1), 5 hydroxy-
sphyngomyelins [SM(OH)C14:1… SM(OH)C24:1], 38 diacyl-
phosphatidylcholines (PC aa C24:0 …PC aa C42:6), 39 acyl-alkyl-
phospatidylcholines (PC ae C30:0… PC ae C44:6), and 15 lyso-
phosphatidylcholines (lysoPC a C6:0….lysoPC a C28:1) were
identified. Plasma concentrations of all analysed metabolites are
reported in mM. Gray fonts, 27 unstable metabolites removed from
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PLoS ONE | www.plosone.org 12 November 2011 | Volume 6 | Issue 11 | e27126all data analyses, based on the low (#0.25) coefficient of variance
of the same 10 reference samples or large proportion (.10%) of
measured samples below LOD. All the metabolites above were
determined using flow injection analysis/thermospray mass
spectrometry (FIA-MS) with Biocrates AbsoluteIDQ
TM targeted
metabolomics technology. In addition, plasma levels of b-
hydroxybutyrate levels were determined using Autokit 3-HB
(Wako Chemicals, Germany, Neuss) and Ketone Body Calibrator
(Wako Chemicals, Germany, Neuss) in both FASTED and RE-
FED state. Data are means 6 SE (n=7–8).
(XLS)
Text S1 Statistical analysis.
(DOC)
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